Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Shares Sold by Oppenheimer & Co. Inc.

Oppenheimer & Co. Inc. trimmed its holdings in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) by 73.5% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 6,922 shares of the medical device company's stock after selling 19,203 shares during the period. Oppenheimer & Co. Inc.'s holdings in Tandem Diabetes Care were worth $249,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also made changes to their positions in the business. Brooklyn Investment Group purchased a new stake in shares of Tandem Diabetes Care during the 3rd quarter worth approximately $28,000. Assetmark Inc. acquired a new stake in Tandem Diabetes Care during the 3rd quarter worth $29,000. McIlrath & Eck LLC purchased a new stake in Tandem Diabetes Care in the third quarter valued at $52,000. Venturi Wealth Management LLC boosted its stake in Tandem Diabetes Care by 5,955.9% in the fourth quarter. Venturi Wealth Management LLC now owns 2,059 shares of the medical device company's stock valued at $74,000 after acquiring an additional 2,025 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Tandem Diabetes Care during the third quarter worth about $105,000.

Insider Buying and Selling at Tandem Diabetes Care

In related news, COO Jean-Claude Kyrillos acquired 10,538 shares of the company's stock in a transaction that occurred on Friday, March 7th. The stock was purchased at an average price of $18.12 per share, for a total transaction of $190,948.56. Following the transaction, the chief operating officer now owns 10,538 shares in the company, valued at $190,948.56. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 2.20% of the company's stock.

Remove Ads

Tandem Diabetes Care Price Performance

Tandem Diabetes Care stock traded up $0.93 during trading hours on Wednesday, hitting $18.82. The stock had a trading volume of 1,473,470 shares, compared to its average volume of 1,474,217. Tandem Diabetes Care, Inc. has a 1-year low of $17.64 and a 1-year high of $53.69. The company has a debt-to-equity ratio of 1.29, a current ratio of 2.90 and a quick ratio of 2.32. The stock's fifty day moving average is $32.43 and its two-hundred day moving average is $35.10. The stock has a market capitalization of $1.25 billion, a price-to-earnings ratio of -9.71 and a beta of 1.45.

Analyst Upgrades and Downgrades

TNDM has been the subject of a number of research analyst reports. Royal Bank of Canada decreased their target price on Tandem Diabetes Care from $65.00 to $55.00 and set an "outperform" rating for the company in a research report on Thursday, February 27th. Wells Fargo & Company reissued an "equal weight" rating and issued a $22.00 price objective (down from $38.00) on shares of Tandem Diabetes Care in a report on Monday, March 3rd. Citigroup cut shares of Tandem Diabetes Care from a "buy" rating to a "neutral" rating and cut their target price for the company from $35.00 to $24.00 in a report on Tuesday, March 4th. Morgan Stanley downgraded shares of Tandem Diabetes Care from an "overweight" rating to an "equal weight" rating and reduced their price target for the company from $45.00 to $22.00 in a research report on Wednesday, March 5th. Finally, The Goldman Sachs Group lowered their price objective on shares of Tandem Diabetes Care from $42.00 to $24.00 and set a "neutral" rating on the stock in a research report on Monday, March 3rd. Eight equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $45.38.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.